I love when drug commercials are like, “don’t take nemolizumab-ilto if you’re allergic to nemolizumab-ilto,” like oh, ok, thank you for the warning
June 18, 2025 at 2:44 AM
I love when drug commercials are like, “don’t take nemolizumab-ilto if you’re allergic to nemolizumab-ilto,” like oh, ok, thank you for the warning
Kratzkrieg beendet?
Die Leitlinie zum chronischen Pruritus ist upgedatet: Nemolizumab erstmals empfohlen, JAK-Hemmer als Off-Label-Option, Reha jetzt mit eigenem Kapitel.
https://www.doccheck.com/de/detail/articles/54446-pruritus-das-jucken-stoppen
Die Leitlinie zum chronischen Pruritus ist upgedatet: Nemolizumab erstmals empfohlen, JAK-Hemmer als Off-Label-Option, Reha jetzt mit eigenem Kapitel.
https://www.doccheck.com/de/detail/articles/54446-pruritus-das-jucken-stoppen
Pruritus: Das Jucken stoppen
Es juckt, und zwar ständig? Die Leitlinie zum chronischen Pruritus ist aktualisiert: Nemolizumab wird erstmals empfohlen, JAK-Hemmer kommen als Off-Label-Option dazu und die Reha bekommt ein eigenes Kapitel.
www.doccheck.com
October 2, 2026 at 3:00 PM
Kratzkrieg beendet?
Die Leitlinie zum chronischen Pruritus ist upgedatet: Nemolizumab erstmals empfohlen, JAK-Hemmer als Off-Label-Option, Reha jetzt mit eigenem Kapitel.
https://www.doccheck.com/de/detail/articles/54446-pruritus-das-jucken-stoppen
Die Leitlinie zum chronischen Pruritus ist upgedatet: Nemolizumab erstmals empfohlen, JAK-Hemmer als Off-Label-Option, Reha jetzt mit eigenem Kapitel.
https://www.doccheck.com/de/detail/articles/54446-pruritus-das-jucken-stoppen
“... or to any of the ingredients in nemolizumab-ilto”
June 18, 2025 at 2:49 AM
“... or to any of the ingredients in nemolizumab-ilto”
This raises the questions a) how many people are allergic to nemolizumab and b) how many times have people who know that they are allergic taken the meds anyway and complained?
June 18, 2025 at 3:07 AM
This raises the questions a) how many people are allergic to nemolizumab and b) how many times have people who know that they are allergic taken the meds anyway and complained?
The part that’s mind blowing is that someone took nemolizumab-ilto knowing full well they were allergic to nemolizumab-ilto…thus they now have to tell everybody to not take nemolizumab-ilto if they are allergic to nemolizumab-ilto…
June 18, 2025 at 2:47 AM
The part that’s mind blowing is that someone took nemolizumab-ilto knowing full well they were allergic to nemolizumab-ilto…thus they now have to tell everybody to not take nemolizumab-ilto if they are allergic to nemolizumab-ilto…
4/4
It will be interesting to see if nemolizumab, an interleukin-31 receptor alpha antagonist, helps mitigate lymphoma-associated pruritus in the rare case when it becomes refractory.
This drug has been tested in atopic dermatitis with pruritus and was effective.
t.ly/-i6US
It will be interesting to see if nemolizumab, an interleukin-31 receptor alpha antagonist, helps mitigate lymphoma-associated pruritus in the rare case when it becomes refractory.
This drug has been tested in atopic dermatitis with pruritus and was effective.
t.ly/-i6US
November 19, 2024 at 4:10 PM
4/4
It will be interesting to see if nemolizumab, an interleukin-31 receptor alpha antagonist, helps mitigate lymphoma-associated pruritus in the rare case when it becomes refractory.
This drug has been tested in atopic dermatitis with pruritus and was effective.
t.ly/-i6US
It will be interesting to see if nemolizumab, an interleukin-31 receptor alpha antagonist, helps mitigate lymphoma-associated pruritus in the rare case when it becomes refractory.
This drug has been tested in atopic dermatitis with pruritus and was effective.
t.ly/-i6US
"or of you are allergic to any of the components of nemolizumab-ilto" ok... now how do I know the components of this drug being advertised on the TV?
June 18, 2025 at 2:55 AM
"or of you are allergic to any of the components of nemolizumab-ilto" ok... now how do I know the components of this drug being advertised on the TV?
Prurigo Nodularis (PN) is notoriously difficult to treat. Can targeting the "itch cytokine" (IL-31) finally bring relief?
doi.org/10.7759/cureus.78761
#WeiPublications #DermSky #Dermatology #MedSky #PrurigoNodularis #Itch #Nemolizumab #FOAMed
doi.org/10.7759/cureus.78761
#WeiPublications #DermSky #Dermatology #MedSky #PrurigoNodularis #Itch #Nemolizumab #FOAMed
Efficacy and Safety of Nemolizumab in Patients With Prurigo Nodularis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
This meta-analysis evaluated the efficacy and safety of nemolizumab in treating prurigo nodularis through a systematic review of randomized controlled trials. A comprehensive literature search was con...
doi.org
January 3, 2026 at 10:26 PM
Prurigo Nodularis (PN) is notoriously difficult to treat. Can targeting the "itch cytokine" (IL-31) finally bring relief?
doi.org/10.7759/cureus.78761
#WeiPublications #DermSky #Dermatology #MedSky #PrurigoNodularis #Itch #Nemolizumab #FOAMed
doi.org/10.7759/cureus.78761
#WeiPublications #DermSky #Dermatology #MedSky #PrurigoNodularis #Itch #Nemolizumab #FOAMed
EADV 2026: Galderma’s New Data Show Sustained Improvements with Nemluvio® (nemolizumab) for up to Three Years in Pati...
Canada’s fastest news scan: 25+ headlines, no clutter, updated all day: CanadaReport.org
#cdnpoli #Canada #News #Business #Economy
Read Original Article 🔗
Canada’s fastest news scan: 25+ headlines, no clutter, updated all day: CanadaReport.org
#cdnpoli #Canada #News #Business #Economy
Read Original Article 🔗
September 30, 2026 at 10:01 AM
EADV 2026: Galderma’s New Data Show Sustained Improvements with Nemluvio® (nemolizumab) for up to Three Years in Pati...
Canada’s fastest news scan: 25+ headlines, no clutter, updated all day: CanadaReport.org
#cdnpoli #Canada #News #Business #Economy
Read Original Article 🔗
Canada’s fastest news scan: 25+ headlines, no clutter, updated all day: CanadaReport.org
#cdnpoli #Canada #News #Business #Economy
Read Original Article 🔗
La CE aprueba nemolizumab para dermatitis atópica y prurigo nodular de moderadas a graves www.diariomedico.com/medicina/emp...
La CE aprueba nemolizumab para dermatitis atópica y prurigo nodular de moderadas a graves
El medicamento es el primer anticuerpo monoclonal aprobado que específicamente bloquea la señalización de IL-31, involucrada en el prurito y la inflamación en ambas enfermedades.
www.diariomedico.com
February 19, 2025 at 6:25 PM
La CE aprueba nemolizumab para dermatitis atópica y prurigo nodular de moderadas a graves www.diariomedico.com/medicina/emp...
Interleukin-31 (IL-31) pathway inhibition may offer an alternative therapeutic direction for refractory indolent #SystemicMastocytosis (ISM) when standard treatments fail. Case report in @cureusmedical.bsky.social.
Read here: https://bit.ly/3LZSmGT
#RareDisease #ISM #Interleukin31
Read here: https://bit.ly/3LZSmGT
#RareDisease #ISM #Interleukin31
Nemolizumab May Offer an Alternative Therapeutic Option for Refractory ISM
A case report suggests nemolizumab may represent an alternative therapeutic option in refractory ISM when standard treatments fail.
bit.ly
January 22, 2026 at 7:55 PM
Interleukin-31 (IL-31) pathway inhibition may offer an alternative therapeutic direction for refractory indolent #SystemicMastocytosis (ISM) when standard treatments fail. Case report in @cureusmedical.bsky.social.
Read here: https://bit.ly/3LZSmGT
#RareDisease #ISM #Interleukin31
Read here: https://bit.ly/3LZSmGT
#RareDisease #ISM #Interleukin31
February 6, 2025 at 3:30 PM
Nemolizumab for refractory scrotal dysesthesia: 2 patients find relief! Promising results in a challenging condition. PMID:40560548, JAMA Dermatol 2025 https://doi.org/10.1001/jamadermatol.2025.1480 #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
https://doi.org/10.1001/jamadermatol.2025.1480
No description available
doi.org
August 19, 2025 at 12:10 AM
💊 Two new comedications added to the Hepatology Drug Interaction checker: Nemolizumab and Sotatercept, both to the class 'Other'.
May 6, 2026 at 2:00 PM
💊 Two new comedications added to the Hepatology Drug Interaction checker: Nemolizumab and Sotatercept, both to the class 'Other'.
Zhou et al report Nemolizumab Treatment Normalizes Dysregulated Microbiome in Lesional Prurigo Nodularis
doi.org/10.1016/j.ji...
#DermatologyJournal #dermatology #dermsky #dermatologists #dermresearch #dermscience #dermatologyresearch
doi.org/10.1016/j.ji...
#DermatologyJournal #dermatology #dermsky #dermatologists #dermresearch #dermscience #dermatologyresearch
Redirecting
doi.org
January 13, 2026 at 9:59 AM
Zhou et al report Nemolizumab Treatment Normalizes Dysregulated Microbiome in Lesional Prurigo Nodularis
doi.org/10.1016/j.ji...
#DermatologyJournal #dermatology #dermsky #dermatologists #dermresearch #dermscience #dermatologyresearch
doi.org/10.1016/j.ji...
#DermatologyJournal #dermatology #dermsky #dermatologists #dermresearch #dermscience #dermatologyresearch
Ja, Vergleiche mit anderen Therapien sind daher nur indirekt und somit eingeschränkt möglich. Dies gilt auch für das ebenfalls in dieser Ausgabe bewertete Nemolizumab.
April 24, 2025 at 12:23 PM
Ja, Vergleiche mit anderen Therapien sind daher nur indirekt und somit eingeschränkt möglich. Dies gilt auch für das ebenfalls in dieser Ausgabe bewertete Nemolizumab.
… palopegteriparatide (Yorvipath), a parathyroid hormone analog, is indicated for hypoparathyroidism; and Nemolizumab (Nemluvio) is an interleukin-31 receptor antagonist indicated for treatment of prurigo nodularis.
End
3/3
End
3/3
December 30, 2024 at 2:13 PM
… palopegteriparatide (Yorvipath), a parathyroid hormone analog, is indicated for hypoparathyroidism; and Nemolizumab (Nemluvio) is an interleukin-31 receptor antagonist indicated for treatment of prurigo nodularis.
End
3/3
End
3/3
Thoughts on this? >> Galderma’s Phase III OLYMPIA 1 Data Published in JAMA
Dermatology Demonstrate That Nemolizumab Improves Core Signs and
Symptoms of Prurigo Nodularis: Full results from the phase III OLYMPIA 1 trial evaluating the… >> Comment below! #industry40 #mhealth #AI #healthtech #IoT
Dermatology Demonstrate That Nemolizumab Improves Core Signs and
Symptoms of Prurigo Nodularis: Full results from the phase III OLYMPIA 1 trial evaluating the… >> Comment below! #industry40 #mhealth #AI #healthtech #IoT
Galderma’s Phase III OLYMPIA 1 Data Published in JAMA
Dermatology Demonstrate That Nemolizumab Improves Core Signs and
Symptoms of Prurigo Nodularis
Full results from the phase III OLYMPIA 1 trial evaluating the efficacy and safety of nemolizumab in adults with moderate-to-severe prurigo nodularis have been published in JAMA Dermatology, showing the trial met all primary and key secondary endpoints1…
dlvr.it
November 28, 2024 at 7:49 AM
Thoughts on this? >> Galderma’s Phase III OLYMPIA 1 Data Published in JAMA
Dermatology Demonstrate That Nemolizumab Improves Core Signs and
Symptoms of Prurigo Nodularis: Full results from the phase III OLYMPIA 1 trial evaluating the… >> Comment below! #industry40 #mhealth #AI #healthtech #IoT
Dermatology Demonstrate That Nemolizumab Improves Core Signs and
Symptoms of Prurigo Nodularis: Full results from the phase III OLYMPIA 1 trial evaluating the… >> Comment below! #industry40 #mhealth #AI #healthtech #IoT
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Mo...
Read more on CanadaReport.org (Updated every 30 mins)
#cdnpoli #Canada #News #Business #Economy
Read Original Article 🔗
Read more on CanadaReport.org (Updated every 30 mins)
#cdnpoli #Canada #News #Business #Economy
Read Original Article 🔗
March 28, 2026 at 6:01 PM
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Mo...
Read more on CanadaReport.org (Updated every 30 mins)
#cdnpoli #Canada #News #Business #Economy
Read Original Article 🔗
Read more on CanadaReport.org (Updated every 30 mins)
#cdnpoli #Canada #News #Business #Economy
Read Original Article 🔗
Interleukin-31-Hemmer #Nemolizumab (NEMLUVIO) bei atopischer Dermatitis
Der neue Antikörper stellt damit ein neues Wirkprinzip bei atopischer Dermatitis dar. Wieder einmal fehlen direkte Vergleiche mit anderen Therapien, da nur mit Placebo verglichen wird.
www.arznei-telegramm.de/html/2025_04...
Der neue Antikörper stellt damit ein neues Wirkprinzip bei atopischer Dermatitis dar. Wieder einmal fehlen direkte Vergleiche mit anderen Therapien, da nur mit Placebo verglichen wird.
www.arznei-telegramm.de/html/2025_04...
Interleukin-31-Hemmer ▼Nemolizumab (NEMLUVIO) bei atopischer Dermatitis
Der neue Antikörper hemmt IL-31 und stellt damit ein neues Wirkprinzip bei atopischer Dermatitis dar. Wieder einmal fehlen direkte Vergleiche mit anderen Therapien, da nur mit Placebo verglichen wird.
www.arznei-telegramm.de
April 24, 2025 at 12:27 PM
Interleukin-31-Hemmer #Nemolizumab (NEMLUVIO) bei atopischer Dermatitis
Der neue Antikörper stellt damit ein neues Wirkprinzip bei atopischer Dermatitis dar. Wieder einmal fehlen direkte Vergleiche mit anderen Therapien, da nur mit Placebo verglichen wird.
www.arznei-telegramm.de/html/2025_04...
Der neue Antikörper stellt damit ein neues Wirkprinzip bei atopischer Dermatitis dar. Wieder einmal fehlen direkte Vergleiche mit anderen Therapien, da nur mit Placebo verglichen wird.
www.arznei-telegramm.de/html/2025_04...
🔬Emerging biologic treatments are changing the landscape for prurigo nodularis. A recent review highlights the effectiveness of IL-4Rα and IL-31RA antagonists, including dupilumab and nemolizumab. Read more: www.emjreviews.com/en-us/amj/de...
#AMJDermatology @amjreviews.bsky.social
#AMJDermatology @amjreviews.bsky.social
New Data Supports Targeted Prurigo Nodularis Therapies
New biologic and targeted therapies are changing the landscape of prurigo nodularis care, offering sustained relief and personalized approaches for this chronic condition.
www.emjreviews.com
May 16, 2025 at 2:31 PM
🔬Emerging biologic treatments are changing the landscape for prurigo nodularis. A recent review highlights the effectiveness of IL-4Rα and IL-31RA antagonists, including dupilumab and nemolizumab. Read more: www.emjreviews.com/en-us/amj/de...
#AMJDermatology @amjreviews.bsky.social
#AMJDermatology @amjreviews.bsky.social
#Nemolizumab vs #dupilumab had greater rates of improvement for multiple measures of Peak Pruritus Numerical Rating Scale scores in patients with #PrurigoNodularis.
https://www.dermatologyadvisor.com/news/nemolizumab-may-have-greater-efficacy-than-dupilumab-prurigo-nodularis/
https://www.dermatologyadvisor.com/news/nemolizumab-may-have-greater-efficacy-than-dupilumab-prurigo-nodularis/
Nemolizumab May Have Greater Efficacy Than Dupilumab for Prurigo Nodularis
Nemolizumab may be more effective across key pruritus and disease severity measures than dupilumab for patients with PN.
www.dermatologyadvisor.com
August 17, 2026 at 10:19 PM
#Nemolizumab vs #dupilumab had greater rates of improvement for multiple measures of Peak Pruritus Numerical Rating Scale scores in patients with #PrurigoNodularis.
https://www.dermatologyadvisor.com/news/nemolizumab-may-have-greater-efficacy-than-dupilumab-prurigo-nodularis/
https://www.dermatologyadvisor.com/news/nemolizumab-may-have-greater-efficacy-than-dupilumab-prurigo-nodularis/
Im März kam Nemolizumab auf den deutschen Markt. Der erste Anti-Interleukin(IL)-31-Rezeptorantikörper hemmt einen Signalweg, der bei #Juckreiz und Hautentzündungen eine Rolle spielt. Zugelassen ist Nemolizumab bei atopischer Dermatitis und bei Prurigo nodularis.
Ein Antikörper, zwei Indikationen: Nemolizumab im Handel
Nemolizumab ist der erste gegen den Interleukin-31-Rezeptor gerichtete Antikörper auf dem deutschen Markt. Zugelassen ist er bei atopischer Dermatitis...
www.pharmazeutische-zeitung.de
April 3, 2025 at 8:43 AM
Im März kam Nemolizumab auf den deutschen Markt. Der erste Anti-Interleukin(IL)-31-Rezeptorantikörper hemmt einen Signalweg, der bei #Juckreiz und Hautentzündungen eine Rolle spielt. Zugelassen ist Nemolizumab bei atopischer Dermatitis und bei Prurigo nodularis.